Therapeutic area |
Cancer |
Goal |
The development of a vaccine formulation to generate a therapeutic immune response against the human papillomavirus 16. |
Description |
Approximately 500 000 women worldwide develop cervical cancer each year and it is the second leading cause of cancer death in women and accounts for over 200 000 deaths annually. Squamous cervical cancer results from infection of the cervix by "high risk" genotypes of human papillomavirus (HPV), particularly HPV16.
There is no currently available therapeutic vaccine against these tumors and most studies are in clinical and pre-clinical phase. Our preparations are based on HPV CTL peptide or recombinant protein in combination with VSSP adjuvant (a novel proprietary adjuvant). Immunization of mice to be injected with experimental E7/HPV16 tumors, using the specific preparations, induces reduction in tumor burden and increased survival, when compared to simultaneous control groups of animals.
|
Patent Status |
Patent filed. |
Project Status |
Preclinical Phase finished. A Phase I clinical trial is due to start in 2007.
|
Type of collaboration requested |
Corporate partnership for carrying out clinical trials.
|
Competitives advantages Milestones |
- Experience in genetic engineering and experimental oncology, highly skilled staff, versatility of the technology (either peptide- or protein-based). Milestones to be developed jointly with the partner.
- After the Phase I clinical trial in 2007 in high grade cervical intraepithelial neoplasia, therapeutic clinical trials Phase II in patients should be conducted.
|
Host Insitutions |
Center for Genetic Engineering and Biotechnology (CIGB). Ave 31, e/158 y 190 Cubanacán, Playa, PO Box 6996, La Habana, 10600, Cuba. Tel. (53-7) 2712397; 2716022. Fax: (53-7) 2718070; (53-7) 2736008. E-mail: ernesto.lopez@cigb.edu.cu
Web site: http://gndp.cigb.edu.cu.
|
Project code:
|
BIO/CIGB/2008-06
|
